SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Veru Inc. – ‘10-Q’ for 6/30/21 – ‘EX-101.SCH’

On:  Thursday, 8/12/21, at 12:20pm ET   ·   For:  6/30/21   ·   Accession #:  863894-21-9   ·   File #:  1-13602

Previous ‘10-Q’:  ‘10-Q’ on 5/12/21 for 3/31/21   ·   Next:  ‘10-Q’ on 2/9/22 for 12/31/21   ·   Latest:  ‘10-Q’ on 5/8/24 for 3/31/24   ·   10 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 8/12/21  Veru Inc.                         10-Q        6/30/21   82:12M

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.09M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     27K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     25K 
11: R1          Document and Entity Information                     HTML     76K 
12: R2          Condensed Consolidated Balance Sheets               HTML    125K 
13: R3          Condensed Consolidated Balance Sheets               HTML     37K 
                (Parenthetical)                                                  
14: R4          Condensed Consolidated Statements of Operations     HTML     96K 
15: R5          Condensed Consolidated Statements of Stockolders'   HTML     91K 
                Equity                                                           
16: R6          Condensed Consolidated Statements of Cash Flows     HTML    124K 
17: R7          Basis of Presentation                               HTML     38K 
18: R8          Sale of PREBOOST Business                           HTML     29K 
19: R9          Fair Value Measurements                             HTML     83K 
20: R10         Revenue from Contracts with Customers               HTML    137K 
21: R11         Accounts Receivable and Concentration of Credit     HTML     63K 
                Risk                                                             
22: R12         Balance Sheet Information                           HTML    113K 
23: R13         Intangible Assets and Goodwill                      HTML    108K 
24: R14         Debt                                                HTML    181K 
25: R15         Stockholders' Equity                                HTML     49K 
26: R16         Share-based Compensation                            HTML    211K 
27: R17         Leases                                              HTML    122K 
28: R18         Contingent Liabilities                              HTML     29K 
29: R19         Income Taxes                                        HTML    256K 
30: R20         Paycheck Protection Program                         HTML     26K 
31: R21         Net (Loss) Income) Per Share                        HTML    121K 
32: R22         Industry Segments                                   HTML     83K 
33: R23         Basis of Presentation (Policy)                      HTML     43K 
34: R24         Fair Value Measurements (Tables)                    HTML     75K 
35: R25         Revenue from Contracts with Customers (Tables)      HTML    129K 
36: R26         Accounts Receivable and Concentration of Credit     HTML     49K 
                Risk (Tables)                                                    
37: R27         Balance Sheet Information (Tables)                  HTML    112K 
38: R28         Intangible Assets and Goodwill (Tables)             HTML    101K 
39: R29         Debt (Tables)                                       HTML    150K 
40: R30         Share-based Compensation (Tables)                   HTML    193K 
41: R31         Leases (Tables)                                     HTML    114K 
42: R32         Income Taxes (Tables)                               HTML    246K 
43: R33         Net (Loss) Income Per Share (Tables)                HTML    117K 
44: R34         Industry Segments (Tables)                          HTML     74K 
45: R35         Sale of PREBOOST Business (Narrative) (Details)     HTML     48K 
46: R36         Fair Value Measurements (Reconciliation of the      HTML     26K 
                Beginning and Ending Liability Balance) (Details)                
47: R37         Fair Value Measurements (Schedule of Qualitative    HTML     37K 
                Information) (Details)                                           
48: R38         Revenue from Contracts with Customers (Narrative)   HTML     24K 
                (Details)                                                        
49: R39         Revenue from Contracts with Customers (Revenue      HTML     37K 
                from Customers by Products) (Details)                            
50: R40         Revenue from Contracts with Customers (Revenue by   HTML     41K 
                Geographic Area) (Details)                                       
51: R41         Accounts Receivable and Concentration of Credit     HTML     52K 
                Risk (Narrative) (Details)                                       
52: R42         Accounts Receivable and Concentration of Credit     HTML     30K 
                Risk (Components of Accounts Receivable) (Details)               
53: R43         Balance Sheet Information (Components Of            HTML     39K 
                Inventory) (Details)                                             
54: R44         Balance Sheet Information (Summary of Plant and     HTML     47K 
                Equipment) (Details)                                             
55: R45         Intangible Assets and Goodwill (Narrative)          HTML     35K 
                (Details)                                                        
56: R46         Intangible Assets and Goodwill (Gross Carrying      HTML     44K 
                Amounts and Net Book Value of Intangible Assets)                 
                (Details)                                                        
57: R47         Debt (Narrative) (Details)                          HTML     96K 
58: R48         Debt (Credit Agreement) (Details)                   HTML     38K 
59: R49         Debt (Residual Royalty Agreement Liability)         HTML     40K 
                (Details)                                                        
60: R50         Debt (Credit Agreement Interest Expense) (Details)  HTML     32K 
61: R51         Stockholders' Equity (Narrative) (Details)          HTML    101K 
62: R52         Share-based Compensation (Narrative) (Details)      HTML     85K 
63: R53         Share-based Compensation (Recorded Share-Based      HTML     32K 
                Compensation Expenses) (Details)                                 
64: R54         Share-based Compensation (Weighted Average          HTML     35K 
                Assumptions for Options Granted) (Details)                       
65: R55         Share-based Compensation (Summary of Stock Options  HTML     57K 
                Outstanding and Exercisable) (Details)                           
66: R56         Leases (Narrative) (Details)                        HTML     41K 
67: R57         Leases (Components of Lease Cost) (Details)         HTML     38K 
68: R58         Leases (Summary of Lease Information) (Details)     HTML     31K 
69: R59         Contingent Liabilities (Narrative) (Details)        HTML     23K 
70: R60         Income Taxes (Narrative) (Details)                  HTML     71K 
71: R61         Income Taxes (Reconciliation of Income Tax Expense  HTML     51K 
                (Benefit)) (Details)                                             
72: R62         Income Taxes (Significant Components of Deferred    HTML     70K 
                Tax Assets and Liabilities) (Details)                            
73: R63         Income Taxes (Schedule of Deferred Tax Amounts      HTML     32K 
                Classified in Balance Sheets) (Details)                          
74: R64         Paycheck Protection Program (Narrative) (Details)   HTML     27K 
75: R65         Net (Loss) Income Per Share (Narrative) (Details)   HTML     23K 
76: R66         Net (Loss) Income Per Share (Schedule Of Earnings   HTML     63K 
                Per Share, Basic And Diluted) (Details)                          
77: R67         Industry Segments (Narrative) (Details)             HTML     23K 
78: R68         Industry Segments (Schedule of Segment Reporting    HTML     34K 
                Information) (Details)                                           
80: XML         IDEA XML File -- Filing Summary                      XML    153K 
10: XML         XBRL Instance -- veru-20210630x10q_htm               XML   3.63M 
79: EXCEL       IDEA Workbook of Financial Reports                  XLSX    100K 
 6: EX-101.CAL  XBRL Calculations -- veru-20210630_cal               XML    206K 
 7: EX-101.DEF  XBRL Definitions -- veru-20210630_def                XML    595K 
 8: EX-101.LAB  XBRL Labels -- veru-20210630_lab                     XML   1.25M 
 9: EX-101.PRE  XBRL Presentations -- veru-20210630_pre              XML    995K 
 5: EX-101.SCH  XBRL Schema -- veru-20210630                         XSD    198K 
81: JSON        XBRL Instance as JSON Data -- MetaLinks              382±   551K 
82: ZIP         XBRL Zipped Folder -- 0000863894-21-000009-xbrl      Zip    239K

‘EX-101.SCH’   —   XBRL Schema — veru-20210630

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- XBRL document created by Certent Disclosure Management 21.2.0.2 -->
<!-- Based on XBRL 2.1 -->
<!-- Created on: 8/12/2021 12:10:25 PM -->
<!-- Modified on: 8/12/2021 12:10:25 PM -->
<schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" targetNamespace="http://verupharma.com/20210630" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" elementFormDefault="qualified" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:veru="http://verupharma.com/20210630" xmlns="http://www.w3.org/2001/XMLSchema">
<xs:annotation>
<xs:appinfo>
<link:roleType roleURI="http://verupharma.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
<link:definition> 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
<link:definition> 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
<link:definition> 00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureAccountsReceivableAndConcentrationOfCreditRiskComponentsOfAccountsReceivableDetails" id="DisclosureAccountsReceivableAndConcentrationOfCreditRiskComponentsOfAccountsReceivableDetails">
<link:definition> 40502 - Disclosure - Accounts Receivable and Concentration of Credit Risk (Components of Accounts Receivable) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureBalanceSheetInformationComponentsOfInventoryDetails" id="DisclosureBalanceSheetInformationComponentsOfInventoryDetails">
<link:definition> 40601 - Disclosure - Balance Sheet Information (Components Of Inventory) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureBalanceSheetInformationSummaryOfPlantAndEquipmentDetails" id="DisclosureBalanceSheetInformationSummaryOfPlantAndEquipmentDetails">
<link:definition> 40602 - Disclosure - Balance Sheet Information (Summary of Plant and Equipment) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureDebtCreditAgreementDetails" id="DisclosureDebtCreditAgreementDetails">
<link:definition> 40802 - Disclosure - Debt (Credit Agreement) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureDebtResidualRoyaltyAgreementLiabilityDetails" id="DisclosureDebtResidualRoyaltyAgreementLiabilityDetails">
<link:definition> 40803 - Disclosure - Debt (Residual Royalty Agreement Liability) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureDebtResidualRoyaltyAgreementLiabilityDetailsAlt" id="DisclosureDebtResidualRoyaltyAgreementLiabilityDetailsAlt">
<link:definition> 40803 - Disclosure - Debt (Residual Royalty Agreement Liability) (Details) alt </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureDebtCreditAgreementInterestExpenseDetails" id="DisclosureDebtCreditAgreementInterestExpenseDetails">
<link:definition> 40804 - Disclosure - Debt (Credit Agreement Interest Expense) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureLeasesComponentsOfLeaseCostDetails" id="DisclosureLeasesComponentsOfLeaseCostDetails">
<link:definition> 41102 - Disclosure - Leases (Components of Lease Cost) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails">
<link:definition> 41303 - Disclosure - Income Taxes (Reconciliation of Income Tax Expense (Benefit)) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
<link:definition> 41305 - Disclosure - Income Taxes (Significant Components of Deferred Tax Assets and Liabilities) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureNetLossIncomePerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" id="DisclosureNetLossIncomePerShareScheduleOfEarningsPerShareBasicAndDilutedDetails">
<link:definition> 41502 - Disclosure - Net (Loss) Income Per Share (Schedule Of Earnings Per Share, Basic And Diluted) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
<link:definition> 00090 - Document - Document and Entity Information </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
<link:definition> 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/StatementCondensedConsolidatedStatementsOfStockoldersEquity" id="StatementCondensedConsolidatedStatementsOfStockoldersEquity">
<link:definition> 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKOLDERS' EQUITY </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
<link:definition> 10101 - Disclosure - Basis of Presentation </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureSaleOfPreboostBusiness" id="DisclosureSaleOfPreboostBusiness">
<link:definition> 10201 - Disclosure - Sale of PREBOOST Business </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
<link:definition> 10301 - Disclosure - Fair Value Measurements </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureRevenueFromContractsWithCustomers" id="DisclosureRevenueFromContractsWithCustomers">
<link:definition> 10401 - Disclosure - Revenue from Contracts with Customers </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureAccountsReceivableAndConcentrationOfCreditRisk" id="DisclosureAccountsReceivableAndConcentrationOfCreditRisk">
<link:definition> 10501 - Disclosure - Accounts Receivable and Concentration of Credit Risk </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureBalanceSheetInformation" id="DisclosureBalanceSheetInformation">
<link:definition> 10601 - Disclosure - Balance Sheet Information </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureIntangibleAssetsAndGoodwill" id="DisclosureIntangibleAssetsAndGoodwill">
<link:definition> 10701 - Disclosure - Intangible Assets and Goodwill </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureDebt" id="DisclosureDebt">
<link:definition> 10801 - Disclosure - Debt </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
<link:definition> 10901 - Disclosure - Stockholders' Equity </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
<link:definition> 11001 - Disclosure - Share-based Compensation </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureLeases" id="DisclosureLeases">
<link:definition> 11101 - Disclosure - Leases </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureContingentLiabilities" id="DisclosureContingentLiabilities">
<link:definition> 11201 - Disclosure - Contingent Liabilities </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
<link:definition> 11301 - Disclosure - Income Taxes </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosurePaycheckProtectionProgram" id="DisclosurePaycheckProtectionProgram">
<link:definition> 11401 - Disclosure - Paycheck Protection Program </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureNetLossIncomePerShare" id="DisclosureNetLossIncomePerShare">
<link:definition> 11501 - Disclosure - Net (Loss) Income) Per Share </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureIndustrySegments" id="DisclosureIndustrySegments">
<link:definition> 11601 - Disclosure - Industry Segments </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureBasisOfPresentationPolicy" id="DisclosureBasisOfPresentationPolicy">
<link:definition> 20102 - Disclosure - Basis of Presentation (Policy) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
<link:definition> 30303 - Disclosure - Fair Value Measurements (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureRevenueFromContractsWithCustomersTables" id="DisclosureRevenueFromContractsWithCustomersTables">
<link:definition> 30403 - Disclosure - Revenue from Contracts with Customers (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureAccountsReceivableAndConcentrationOfCreditRiskTables" id="DisclosureAccountsReceivableAndConcentrationOfCreditRiskTables">
<link:definition> 30503 - Disclosure - Accounts Receivable and Concentration of Credit Risk (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureBalanceSheetInformationTables" id="DisclosureBalanceSheetInformationTables">
<link:definition> 30603 - Disclosure - Balance Sheet Information (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureIntangibleAssetsAndGoodwillTables" id="DisclosureIntangibleAssetsAndGoodwillTables">
<link:definition> 30703 - Disclosure - Intangible Assets and Goodwill (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureDebtTables" id="DisclosureDebtTables">
<link:definition> 30803 - Disclosure - Debt (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
<link:definition> 31003 - Disclosure - Share-based Compensation (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
<link:definition> 31103 - Disclosure - Leases (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
<link:definition> 31303 - Disclosure - Income Taxes (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureNetLossIncomePerShareTables" id="DisclosureNetLossIncomePerShareTables">
<link:definition> 31503 - Disclosure - Net (Loss) Income Per Share (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureIndustrySegmentsTables" id="DisclosureIndustrySegmentsTables">
<link:definition> 31603 - Disclosure - Industry Segments (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureSaleOfPreboostBusinessNarrativeDetails" id="DisclosureSaleOfPreboostBusinessNarrativeDetails">
<link:definition> 40201 - Disclosure - Sale of PREBOOST Business (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureFairValueMeasurementsReconciliationOfBeginningAndEndingLiabilityBalanceDetails" id="DisclosureFairValueMeasurementsReconciliationOfBeginningAndEndingLiabilityBalanceDetails">
<link:definition> 40302 - Disclosure - Fair Value Measurements (Reconciliation of the Beginning and Ending Liability Balance) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureFairValueMeasurementsScheduleOfQualitativeInformationDetails" id="DisclosureFairValueMeasurementsScheduleOfQualitativeInformationDetails">
<link:definition> 40303 - Disclosure - Fair Value Measurements (Schedule of Qualitative Information) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureRevenueFromContractsWithCustomersNarrativeDetails" id="DisclosureRevenueFromContractsWithCustomersNarrativeDetails">
<link:definition> 40401 - Disclosure - Revenue from Contracts with Customers (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureRevenueFromContractsWithCustomersRevenueFromCustomersByProductsDetails" id="DisclosureRevenueFromContractsWithCustomersRevenueFromCustomersByProductsDetails">
<link:definition> 40402 - Disclosure - Revenue from Contracts with Customers (Revenue from Customers by Products) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureRevenueFromContractsWithCustomersRevenueByGeographicAreaDetails" id="DisclosureRevenueFromContractsWithCustomersRevenueByGeographicAreaDetails">
<link:definition> 40403 - Disclosure - Revenue from Contracts with Customers (Revenue by Geographic Area) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureAccountsReceivableAndConcentrationOfCreditRiskNarrativeDetails" id="DisclosureAccountsReceivableAndConcentrationOfCreditRiskNarrativeDetails">
<link:definition> 40501 - Disclosure - Accounts Receivable and Concentration of Credit Risk (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureIntangibleAssetsAndGoodwillNarrativeDetails" id="DisclosureIntangibleAssetsAndGoodwillNarrativeDetails">
<link:definition> 40701 - Disclosure - Intangible Assets and Goodwill (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureIntangibleAssetsAndGoodwillGrossCarryingAmountsAndNetBookValueOfIntangibleAssetsDetails" id="DisclosureIntangibleAssetsAndGoodwillGrossCarryingAmountsAndNetBookValueOfIntangibleAssetsDetails">
<link:definition> 40704 - Disclosure - Intangible Assets and Goodwill (Gross Carrying Amounts and Net Book Value of Intangible Assets) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureDebtNarrativeDetails" id="DisclosureDebtNarrativeDetails">
<link:definition> 40801 - Disclosure - Debt (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureStockholdersEquityNarrativeDetails" id="DisclosureStockholdersEquityNarrativeDetails">
<link:definition> 40901 - Disclosure - Stockholders' Equity (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureShareBasedCompensationNarrativeDetails" id="DisclosureShareBasedCompensationNarrativeDetails">
<link:definition> 41001 - Disclosure - Share-based Compensation (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureShareBasedCompensationRecordedShareBasedCompensationExpensesDetails" id="DisclosureShareBasedCompensationRecordedShareBasedCompensationExpensesDetails">
<link:definition> 41002 - Disclosure - Share-based Compensation (Recorded Share-Based Compensation Expenses) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsForOptionsGrantedDetails" id="DisclosureShareBasedCompensationWeightedAverageAssumptionsForOptionsGrantedDetails">
<link:definition> 41003 - Disclosure - Share-based Compensation (Weighted Average Assumptions for Options Granted) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureShareBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails" id="DisclosureShareBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails">
<link:definition> 41004 - Disclosure - Share-based Compensation (Summary of Stock Options Outstanding and Exercisable) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureLeasesNarrativeDetails" id="DisclosureLeasesNarrativeDetails">
<link:definition> 41101 - Disclosure - Leases (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureLeasesSummaryOfLeaseInformationDetails" id="DisclosureLeasesSummaryOfLeaseInformationDetails">
<link:definition> 41103 - Disclosure - Leases (Summary of Lease Information) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureContingentLiabilitiesNarrativeDetails" id="DisclosureContingentLiabilitiesNarrativeDetails">
<link:definition> 41201 - Disclosure - Contingent Liabilities (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
<link:definition> 41301 - Disclosure - Income Taxes (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAmountsClassifiedInBalanceSheetsDetails" id="DisclosureIncomeTaxesScheduleOfDeferredTaxAmountsClassifiedInBalanceSheetsDetails">
<link:definition> 41306 - Disclosure - Income Taxes (Schedule of Deferred Tax Amounts Classified in Balance Sheets) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosurePaycheckProtectionProgramNarrativeDetails" id="DisclosurePaycheckProtectionProgramNarrativeDetails">
<link:definition> 41401 - Disclosure - Paycheck Protection Program (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureNetLossIncomePerShareNarrativeDetails" id="DisclosureNetLossIncomePerShareNarrativeDetails">
<link:definition> 41501 - Disclosure - Net (Loss) Income Per Share (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureIndustrySegmentsNarrativeDetails" id="DisclosureIndustrySegmentsNarrativeDetails">
<link:definition> 41601 - Disclosure - Industry Segments (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://verupharma.com/role/DisclosureIndustrySegmentsScheduleOfSegmentReportingInformationDetails" id="DisclosureIndustrySegmentsScheduleOfSegmentReportingInformationDetails">
<link:definition> 41602 - Disclosure - Industry Segments (Schedule of Segment Reporting Information) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="veru-20210630_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"> </link:linkbaseRef>
<link:linkbaseRef xlink:type="simple" xlink:href="veru-20210630_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"> </link:linkbaseRef>
<link:linkbaseRef xlink:type="simple" xlink:href="veru-20210630_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"> </link:linkbaseRef>
<link:linkbaseRef xlink:type="simple" xlink:href="veru-20210630_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"> </link:linkbaseRef>
<!-- [WMV4][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTqW48Yt1AzxMKJx9K0IRflkpQo12tH/HzKOpblQ93EThcpvEbk4/4gYjjN4D7prJpWl6R2hsgi8vxXCbAg51UXUgyqc0gdhwFW8Fl8WxCVsBpMdl9KedT+70dtjMBpK8o/Oaysh1vy9zlDDaJwELtpvyqAerKQZm8hhPt5L0X1pIXAyIhe3m2CwkIhpyo3Vv0BU38Y77d7x1w=] CSR -->
</xs:appinfo>
</xs:annotation>
<xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"> </xs:import>
<xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"> </xs:import>
<xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"> </xs:import>
<xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"> </xs:import>
<xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"> </xs:import>
<xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:import>
<xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:import>
<xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:import>
<xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:import>
<xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:import>
<xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:import>
<xs:element id="veru_DeferredTaxAssetsForeignCapitalAllowance" name="DeferredTaxAssetsForeignCapitalAllowance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_CreditTerms" name="CreditTerms" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element name="OtherCountriesMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="veru_OtherCountriesMember"> </xs:element>
<xs:element name="PreferredClassASeries1Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="veru_PreferredClassASeries1Member"> </xs:element>
<xs:element name="PreferredClassASeries2Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="veru_PreferredClassASeries2Member"> </xs:element>
<xs:element name="PreferredClassASeries3Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="veru_PreferredClassASeries3Member"> </xs:element>
<xs:element id="veru_ScheduleOfEarningsPerShareBasicAndDilutedTable" name="ScheduleOfEarningsPerShareBasicAndDilutedTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" name="ScheduleOfEarningsPerShareBasicAndDilutedLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_IncomeTaxExpenseBenefitLineItems" name="IncomeTaxExpenseBenefitLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_IncomeTaxExpenseBenefitTable" name="IncomeTaxExpenseBenefitTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ComponentsOfDeferredTaxAssetsAndLiabilitiesTable" name="ComponentsOfDeferredTaxAssetsAndLiabilitiesTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ComponentsOfDeferredTaxAssetsAndLiabilitiesLineItems" name="ComponentsOfDeferredTaxAssetsAndLiabilitiesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_TwoThousandEightStockIncentivePlanMember" name="TwoThousandEightStockIncentivePlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_StockIssuedDuringPeriodSharesStockOptionsExercisedCashlessExercise" name="StockIssuedDuringPeriodSharesStockOptionsExercisedCashlessExercise" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ScheduleOfDeferredTaxAmountsClassifiedInBalanceSheetTableTextBlock" name="ScheduleOfDeferredTaxAmountsClassifiedInBalanceSheetTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_AssetsCurrentMember" name="AssetsCurrentMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_StockIssuedDuringPeriodSharesShareBasedCompensationGrossCashlessExercise" name="StockIssuedDuringPeriodSharesShareBasedCompensationGrossCashlessExercise" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_NumberOfCustomers" name="NumberOfCustomers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_PledgePercentage" name="PledgePercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_AppMergerMember" name="AppMergerMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_TotalAccountsReceivableMember" name="TotalAccountsReceivableMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_CommonStockPurchaseWarrantsMember" name="CommonStockPurchaseWarrantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_Fc2Member" name="Fc2Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_PreboostMember" name="PreboostMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_CovenantsNotToCompeteMember" name="CovenantsNotToCompeteMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_TwoThousandAndSeventeenEquityIncentivePlanMember" name="TwoThousandAndSeventeenEquityIncentivePlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DeferredTaxLiabilitiesInProcessRAndD" name="DeferredTaxLiabilitiesInProcessRAndD" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DeferredTaxLiabilitiesDevelopedTechnology" name="DeferredTaxLiabilitiesDevelopedTechnology" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_EmployeeMember" name="EmployeeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_PreferredClassSeries4Member" name="PreferredClassSeries4Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_TermOfPurchaseAgreement" name="TermOfPurchaseAgreement" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_MaximumVwapPercentage" name="MaximumVwapPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_SwkCreditAgreementMember" name="SwkCreditAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_TwentyEighteenEquityIncentivePlanMember" name="TwentyEighteenEquityIncentivePlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_RequiredMinimumLiquidAssets" name="RequiredMinimumLiquidAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_PeriodToReplaceKeyPersons" name="PeriodToReplaceKeyPersons" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_CreditAgreementInterestExpenseTableTextBlock" name="CreditAgreementInterestExpenseTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ResidualRoyaltyAgreementMember" name="ResidualRoyaltyAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ResidualRoyaltyAgreementLiabilityNet" name="ResidualRoyaltyAgreementLiabilityNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_FairValueOfOptionsGranted" name="FairValueOfOptionsGranted" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DeferredCostsRelatedExpenses" name="DeferredCostsRelatedExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_NetProceedsAfterFeesAndExpenses" name="NetProceedsAfterFeesAndExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_AnnualBaseRentEscalationPercent" name="AnnualBaseRentEscalationPercent" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_IndefiniteMember" name="IndefiniteMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_AllowanceForSalesAndPaymentTermDiscounts" name="AllowanceForSalesAndPaymentTermDiscounts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_EquipmentFurnitureAndFixturesMember" name="EquipmentFurnitureAndFixturesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_MeasurementInputProbabilityOfChangeOfControlMember" name="MeasurementInputProbabilityOfChangeOfControlMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DepreciationAndOtherAmortization" name="DepreciationAndOtherAmortization" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ResidualRoyaltyAgreementNoncurrent" name="ResidualRoyaltyAgreementNoncurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_AccruedResearchAndDevelopmentCostsCurrent" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_GeneralPercentageOfVwapPursuantToNotice" name="GeneralPercentageOfVwapPursuantToNotice" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_PercentageOfOutstandingSharesAcquiredWhichConstitutesChangeOfControl" name="PercentageOfOutstandingSharesAcquiredWhichConstitutesChangeOfControl" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_Fc2SegmentMember" name="Fc2SegmentMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_PreboostSegmentMember" name="PreboostSegmentMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_PublicSectorSegmentMember" name="PublicSectorSegmentMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_U.s.PrescriptionChannelSegmentMember" name="U.s.PrescriptionChannelSegmentMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DebtCovenantsPaymentTermsProductRevenueThreshold" name="DebtCovenantsPaymentTermsProductRevenueThreshold" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DebtCovenantsPaymentTermsProductRevenueMeasurementPeriod" name="DebtCovenantsPaymentTermsProductRevenueMeasurementPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DebtCovenantsPaymentTermsPercentageOfProductRevenue" name="DebtCovenantsPaymentTermsPercentageOfProductRevenue" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DebtCovenantsPaymentTermsPercentageOfProductRevenueAfterInitialThreshold" name="DebtCovenantsPaymentTermsPercentageOfProductRevenueAfterInitialThreshold" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DebtCovenantsPaymentTermsElapsedPeriodPaymentThreshold" name="DebtCovenantsPaymentTermsElapsedPeriodPaymentThreshold" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ChangeInControlOrSaleOfBusinessMember" name="ChangeInControlOrSaleOfBusinessMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ProductRevenueOver10000000Member" name="ProductRevenueOver10000000Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ProductRevenueOver10000000Million2019Member" name="ProductRevenueOver10000000Million2019Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ProductRevenueOver10000000Million2020Member" name="ProductRevenueOver10000000Million2020Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ProductRevenueOver10000000Million2021Member" name="ProductRevenueOver10000000Million2021Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ProductRevenueUnder10000000MillionMember" name="ProductRevenueUnder10000000MillionMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DebtCovenantsPaymentTermsChangeInControlOrSaleOfBusinessFeeAmount" name="DebtCovenantsPaymentTermsChangeInControlOrSaleOfBusinessFeeAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DebtCovenantsPaymentTermsChangeInControlOrSaleOfBusinessFeePercentageMultiple" name="DebtCovenantsPaymentTermsChangeInControlOrSaleOfBusinessFeePercentageMultiple" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DebtCovenantsPaymentTermsChangeInControlOrSaleOfBusinessFeePercentageOfProduceRevenue" name="DebtCovenantsPaymentTermsChangeInControlOrSaleOfBusinessFeePercentageOfProduceRevenue" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DevelopedTechnologyMember" name="DevelopedTechnologyMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ProductLiabilityInsuranceCoverageAmount" name="ProductLiabilityInsuranceCoverageAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_FairValueMeasurementLevel3ChangeInControlDate" name="FairValueMeasurementLevel3ChangeInControlDate" nillable="true" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_LeaseTermsTableTextBlock" name="LeaseTermsTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_OperatingLeaseRightOfUseAssetsNonCashChange" name="OperatingLeaseRightOfUseAssetsNonCashChange" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_EstimatedChangeOfControlDatesMember" name="EstimatedChangeOfControlDatesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_PremiumFinanceAgreementMember" name="PremiumFinanceAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DebtInstrumentNumberOfInstallments" name="DebtInstrumentNumberOfInstallments" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_StockPurchaseAgreementRemainingAmountAuthorized" name="StockPurchaseAgreementRemainingAmountAuthorized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DebtConvenantsPaymentTermsPercentageOfAdvancedAmountToBeRepaidBeforeRegularRoyaltyPayment" name="DebtConvenantsPaymentTermsPercentageOfAdvancedAmountToBeRepaidBeforeRegularRoyaltyPayment" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_StockPurchaseAgreementMaximumPurchaseOfSharesPerDay" name="StockPurchaseAgreementMaximumPurchaseOfSharesPerDay" nillable="true" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ResidualRoyaltyAgreementDisclosuresTable" name="ResidualRoyaltyAgreementDisclosuresTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ResidualRoyaltyAgreementDisclosuresLineItems" name="ResidualRoyaltyAgreementDisclosuresLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_CumulativeRepaymentsOfDebt" name="CumulativeRepaymentsOfDebt" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ResidualRoyaltyAgreement" name="ResidualRoyaltyAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ResidualRoyaltyAgreementCurrent" name="ResidualRoyaltyAgreementCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ProceedsFromPppLoanCaresAct" name="ProceedsFromPppLoanCaresAct" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ReductionOfSellingGeneralAndAdministrativeExpenseCaresAct" name="ReductionOfSellingGeneralAndAdministrativeExpenseCaresAct" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ReductionOfResearchAndDevelopmentExpenseCaresAct" name="ReductionOfResearchAndDevelopmentExpenseCaresAct" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_StockPurchaseAgreementAggregateAmountOfStockPurchaseAuthorized" name="StockPurchaseAgreementAggregateAmountOfStockPurchaseAuthorized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ResidualRoyaltyAgreementAccumulatedAccretion" name="ResidualRoyaltyAgreementAccumulatedAccretion" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_IncomeTaxReconciliationEffectOfGlobalIntangibleLowTaxedIncome" name="IncomeTaxReconciliationEffectOfGlobalIntangibleLowTaxedIncome" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_BaseRentAmountPerSquareFoot" name="BaseRentAmountPerSquareFoot" nillable="true" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_AspireCapitalPurchaseAgreement2020Member" name="AspireCapitalPurchaseAgreement2020Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ClassOfWarrantOrRightTerm" name="ClassOfWarrantOrRightTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_SexualHealthSegmentMember" name="SexualHealthSegmentMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ResearchAndDevelopmentSegmentMember" name="ResearchAndDevelopmentSegmentMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_LesseeOperatingAndFinanceLeasesTextBlock" name="LesseeOperatingAndFinanceLeasesTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DisposalGroupIncludingDiscontinuedOperationConsiderationPayablePeriodPayablePaymentOne" name="DisposalGroupIncludingDiscontinuedOperationConsiderationPayablePeriodPayablePaymentOne" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DisposalGroupIncludingDiscontinuedOperationConsiderationPayablePaymentOne" name="DisposalGroupIncludingDiscontinuedOperationConsiderationPayablePaymentOne" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DisposalGroupIncludingDiscontinuedOperationConsiderationPayablePaymentTwo" name="DisposalGroupIncludingDiscontinuedOperationConsiderationPayablePaymentTwo" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DisposalGroupIncludingDiscontinuedOperationConsiderationPayablePeriodPayablePaymentTwo" name="DisposalGroupIncludingDiscontinuedOperationConsiderationPayablePeriodPayablePaymentTwo" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_DisposalGroupNetBookValue" name="DisposalGroupNetBookValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_LesseeOperatingAndFinanceLeasesRemainingLeaseTerms" name="LesseeOperatingAndFinanceLeasesRemainingLeaseTerms" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_EffectiveIncomeTaxRateReconciliationEffectOfWarrantsExercised" name="EffectiveIncomeTaxRateReconciliationEffectOfWarrantsExercised" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_CaresActEffectiveIncomeTaxRateReconciliationEffectOfPaycheckProtectionProgramFunds" name="CaresActEffectiveIncomeTaxRateReconciliationEffectOfPaycheckProtectionProgramFunds" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ProceedsFromIssuanceOfCommonStockUnderPurchaseAgreement" name="ProceedsFromIssuanceOfCommonStockUnderPurchaseAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_AccruedStockIssuanceCosts" name="AccruedStockIssuanceCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_ThreeCustomersMember" name="ThreeCustomersMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_TwoCustomersMember" name="TwoCustomersMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_StockOptionConversionRatio" name="StockOptionConversionRatio" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_PrepaidResearchAndDevelopmentCostsCurrent" name="PrepaidResearchAndDevelopmentCostsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_NoncashOrPartNoncashAcquisitionSharesIssuedForServices" name="NoncashOrPartNoncashAcquisitionSharesIssuedForServices" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_IncreaseInOtherAssetsFromAccruedExpenses" name="IncreaseInOtherAssetsFromAccruedExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_CumulativeRoyaltiesPaid" name="CumulativeRoyaltiesPaid" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_TwentyTwentyTwoToTwentyFortyMember" name="TwentyTwentyTwoToTwentyFortyMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_Expiring2040Member" name="Expiring2040Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_EnactedU.k.TaxRateIncreaseMember" name="EnactedU.k.TaxRateIncreaseMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_IncreaseDecreaseInDeferredTaxAssets" name="IncreaseDecreaseInDeferredTaxAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
<xs:element id="veru_PercentOfRevenueBenchmark" name="PercentOfRevenueBenchmark" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema"> </xs:element>
</schema>

10 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

12/10/20  Veru Inc.                         10-K        9/30/20  100:9.9M
 3/29/19  Veru Inc.                         8-K:5,9     3/26/19    3:161K                                   Donnelley … Solutions/FA
 5/04/18  Veru Inc.                         8-K:5,9     5/02/18    2:168K                                   Donnelley … Solutions/FA
 8/01/17  Veru Inc.                         8-K:3,5,9   7/28/17    3:190K                                   Donnelley … Solutions/FA
11/02/16  Veru Inc.                         8-K:1,2,3,510/31/16    7:824K                                   Donnelley … Solutions/FA
 5/17/04  Veru Inc.                         10QSB       3/31/04    5:289K                                   Reinhart Boerner … SC/FA
 5/15/03  Veru Inc.                         10QSB       3/31/03    2:79K                                    Reinhart Boerner … SC/FA
 9/06/02  Veru Inc.                         SB-2                   4:270K                                   Reinhart Boerner … SC/FA
 9/21/00  Veru Inc.                         SB-2                   5:302K                                   Reinhart Boerner … SC/FA
10/19/99  Veru Inc.                         SB-2                   5:381K                                   Bowne - Bde
↑Top
Filing Submission 0000863894-21-000009   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sun., May 12, 6:17:44.2am ET